BCTX · XBRL financial data
BriaCell Therapeutics financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (BCTX's year ends in late July)
| In thousands of dollars | Jul 31, 2021 | Jul 31, 2022 | Jul 31, 2023 | Jul 31, 2024 | †Jul 31, 2025 | Jul 31, 2026 |
|---|---|---|---|---|---|---|
| Research and development | 2,021 | 8,021 | 15,337 | 27,178 | 21,271 | 29,237 |
| General and administrative | 4,955 | 7,267 | 7,936 | 6,152 | 5,934 | 6,818 |
| Total operating expenses | — | — | 23,272 | 33,330 | 27,205 | 36,054 |
| Operating income (loss) | (6,976) | (15,289) | (23,272) | (33,330) | (27,205) | (36,054) |
| Interest income | 3 | 137 | 891 | 288 | 120 | 634 |
| Interest expense | 79 | 1 | — | — | 37 | 30 |
| Net income (loss) | (13,816) | (26,839) | (20,302) | (4,791) | (26,312) | (34,904) |
| Earnings per share, basic USD per share | (3.06) | (1.73) | (1.30) | (0.29) | (62.19) | (6.97) |
| Earnings per share, diluted USD per share | — | (1.73) | (1.30) | (0.29) | (62.19) | (6.97) |
| Weighted average shares, basic thousands of shares | 4,520 | 15,494 | 15,620 | 16,455 | 423 | 5,011 |
| Weighted average shares, diluted thousands of shares | — | 15,494 | 15,620 | 16,455 | 423 | 5,011 |
| Research and development | 1,315 | — | — | — | — | — |
| Operating profit (loss) | (6,973) | — | — | — | — | — |
| Profit (loss) | (428) | — | — | — | — | — |
- † Share count changed about 1/19 in the period ending 2025-07-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (BCTX's year ends in late July)
| In thousands of dollars | Jul 31, 2021 | Jul 31, 2022 | Jul 31, 2023 | Jul 31, 2024 | †Jul 31, 2025 | Jul 31, 2026 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 57,269 | 41,042 | 21,251 | 862 | 10,494 | 9,852 |
| Short-term investments | — | — | — | — | 7,372 | 10,688 |
| Accounts receivable | 13 | 24 | 19 | — | — | — |
| Total current assets | 57,798 | 42,347 | 26,949 | 3,654 | 19,927 | 22,045 |
| Property and equipment, net | — | 3 | 3 | 388 | 297 | 320 |
| Total assets | 58,044 | 42,577 | 27,164 | 5,872 | 21,650 | 23,580 |
| Total current liabilities | 557 | 941 | 1,801 | 7,461 | 3,978 | 7,982 |
| Accumulated deficit | (29,142) | (60,350) | (80,652) | (85,444) | (111,756) | (146,660) |
| Total stockholders' equity | 27,672 | 10,329 | (3,777) | — | — | — |
| Total liabilities and equity | 58,044 | 42,577 | 27,164 | 5,872 | 21,650 | 23,580 |
| Common shares outstanding (cover page) thousands of shares | 15,270 | 15,518 | 15,982 | 36,183 | 1,884 | 8,732 |
| Cash and cash equivalents | 57,269 | — | — | — | — | — |
| Total current assets | 57,798 | — | — | — | — | — |
| Total assets | 58,044 | — | — | — | — | — |
| Total current liabilities | 557 | — | — | — | — | — |
| Total equity | 57,262 | — | — | — | — | — |
| Total equity and liabilities | 58,044 | — | — | — | — | — |
- † Share count changed about 1/19 in the period ending 2025-07-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (BCTX's year ends in late July)
| In thousands of dollars | Jul 31, 2021 | Jul 31, 2022 | Jul 31, 2023 | Jul 31, 2024 | †Jul 31, 2025 | Jul 31, 2026 |
|---|---|---|---|---|---|---|
| Net income (loss) | (13,816) | (26,839) | (20,302) | (4,791) | (26,312) | (34,904) |
| Stock-based compensation | 1,968 | 3,075 | 2,194 | 1,804 | 777 | 1,130 |
| Depreciation and amortization | 15 | 15 | — | — | — | — |
| Net cash from operating activities | (7,750) | (12,484) | (23,745) | (24,126) | (28,171) | (28,651) |
| Purchases of property and equipment | — | — | — | 457 | — | 127 |
| Net cash from investing activities | — | — | — | (682) | (7,646) | (3,805) |
| Proceeds from issuing common stock | — | — | 4,000 | 4,419 | 44,627 | 31,815 |
| Proceeds from issuing equity | — | — | — | — | 50,900 | 34,710 |
| Net cash from financing activities | 64,998 | (3,743) | 3,954 | 4,419 | 45,448 | 31,815 |
| Net change in cash | — | — | (19,791) | (20,389) | 9,632 | (641) |
| Net cash from operating activities | (7,748) | — | — | — | — | — |
| Net cash from financing activities | 64,995 | — | — | — | — | — |
- † Share count changed about 1/19 in the period ending 2025-07-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| BriaCell Therapeutics | 9,852 | not reported | (5,959)* | 8.7M | 3.4 quarters | 10-KJul 31, 2026 |
| Abvc Biopharma | 32 | not reported | (244)* | 26.7M | 0.4 quarters | 10-QJun 30, 2026 |
| Karyopharm Therapeutics | 54,980 | 33,432 | (24,931)* | 22.7M | 2.6 quarters | 10-QJun 30, 2026 |
| Atara Biotherapeutics | 3,221 | 630 | (3,338)* | 10.0M | 3.0 quarters | 10-QJun 30, 2026 |
| Annovis Bio | 18,729 | 0* | (21,914)* | 42.6M | 0.9 quarters | 10-QJun 30, 2026 |
| CervoMed | 22,463 | 0 | (6,918)* | 15.1M | 3.6 quarters | 10-QJun 30, 2026 |
| Grace Therapeutics | 13,756 | not reported | (3,221) | 21.0M | 4.3 quarters | 10-QJun 30, 2026 |
| Actuate Therapeutics | 4,426 | not reported | (4,405)* | 24.0M | 1.0 quarters | 10-QJun 30, 2026 |
| Kezar Life Sciences | 66,229 | not reported | (7,445) | 7.4M | 8.9 quarters | 10-QMar 31, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.